The companies will share development costs and any profits in major markets with each taking the lead marketing the therapy in different countries. The drug dubbed TEV574 is being tested as a treatment for ulcerative colitis and Crohns disease two types of inflammatory bowel disease. Its one of a class of drugs that target a protein called TL1A